Ivermectin remains one of the most widely traded antiparasitic pharmaceuticals in the global market, serving both human and animal health applications across every major region. As a semi-synthetic macrocyclic lactone derived from Streptomyces avermitilis fermentation products, ivermectin is indicated for treating parasitic infections including onchocerciasis, strongyloidiasis, head lice, and rosacea, alongside extensive veterinary applications in livestock, poultry, and companion animals. The global ivermectin medication market was valued at approximately USD 1.56 billion in 2025 and is projected to reach USD 2.61 billion by 2033, growing at a compound annual growth rate of 6.63%. The ivermectin tablet segment alone generated USD 565 million in 2025, with forecasts reaching USD 711 million by 2032.…